KL
KLDO.US Kaleido Biosciences Inc
- Market cap
- USD 4.26K
- P/E
- -
- P/B
- 0.00x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is KLDO.US undervalued?
Graham numberThe Graham number of Kaleido Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kaleido Biosciences Inc fundamental analysis
No fundamental analysis for Kaleido Biosciences Inc yet.
Kaleido Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kaleido Biosciences Inc
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncolog…
Full company profileKaleido Biosciences Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kaleido Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 975K | 1.10M | - | - |
| Gross Profit | 0.00 | 0.00 | 0.00 | -1.32M | 975K | -1.25M | - | - |
| Operating Income | -9.44M | -27.0M | -60.7M | -86.7M | -78.9M | -87.7M | - | - |
| EBITDA | -9.34M | -26.7M | -59.0M | -85.3M | -77.1M | -85.1M | - | - |
| Net Income | -9.69M | -27.6M | -61.7M | -85.0M | -79.8M | -90.3M | - | - |
| EPS | -0.43 | -1.23 | -2.10 | -3.31 | -2.39 | -2.16 | - | - |
| Balance Sheet | ||||||||
| Total Assets | 4.99M | 30.7M | 85.3M | 82.3M | 59.3M | 50.1M | - | - |
| Total Liabilities | 21.9M | 74.4M | 27.1M | 33.4M | 38.8M | 39.5M | - | - |
| Shareholders' Equity | -16.9M | -43.7M | 58.2M | 48.9M | 20.5M | 10.6M | - | - |
| Cash & Short-term Investments | 2.73M | 28.5M | 76.1M | 71.2M | 46.2M | 38.5M | - | - |
| Total Debt | 4.95M | 14.9M | 14.9M | 20.5M | 21.0M | 21.7M | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -9.35M | -22.5M | -46.3M | -75.8M | -61.5M | -77.1M | - | - |
| Capital Expenditure | 195K | 1.41M | 3.00M | 3.59M | 4.02M | 1.13M | 0.00 | - |
| Free Cash Flow | -9.55M | -23.9M | -49.3M | -79.4M | -65.5M | -78.2M | - | - |
| Ratios | ||||||||
| ROE | - | - | -106.1% | -173.9% | -389.3% | -851.2% | - | - |
| ROA | -194.1% | -89.6% | -72.4% | -103.3% | -134.5% | -180.1% | - | - |
| Net Profit Margin | - | - | - | - | -8,184.2% | -8,178.3% | - | - |
| Debt to Equity | - | - | 0.26x | 0.42x | 1.03x | 2.05x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kaleido Biosciences Inc dividends
Kaleido Biosciences Inc has not paid dividends in the last 7 fiscal years.
Who owns Kaleido Biosciences Inc
- Insiders 0.00%
- Institutions 0.06%
- Public & others 99.95%
- Shares outstanding 42.6M
- Free float 42.4M
Top funds holding KLDO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State St US Sm Cap Enhanced SL Cl I | 107K | 0.25% | 0.00% | Sep 2022 |
| Fidelity® Select Biotechnology | 84.9K | 0.20% | 0.00% | Sep 2022 |
| iShares Russell 2000 Small-Cap Idx Instl | 19.2K | 0.05% | 0.00% | Mar 2022 |
| Northern Small Cap Core K | 14.2K | 0.03% | 0.00% | Sep 2022 |
| Xtrackers Russell 2000 ETF 1C | 10.4K | 0.02% | 0.00% | Sep 2022 |
| NT Quality Small Cap Core | 9.33K | 0.02% | 0.00% | Sep 2022 |
| NT Quality SCC US Fund - L | 9.33K | 0.02% | 0.00% | Sep 2022 |
| The Vanguard Total Stock Market Index | 4.50K | 0.01% | 0.00% | Feb 2022 |
| BlackRock Small Cap Index V.I. I | 3.20K | 0.01% | 0.00% | Mar 2022 |
| MM Russell 2000® Small Cap Index I | 1.85K | 0.00% | 0.00% | Mar 2022 |
| iShares Russell Small/Mid-Cap Idx K | 1.43K | 0.00% | 0.00% | Mar 2022 |
| Rydex Russell 2000 2x Strategy A | 102.00 | 0.00% | 0.00% | Mar 2022 |
| Rydex Russell 2000 1.5x Strategy H | 49.00 | 0.00% | 0.00% | Mar 2022 |
| Rydex Var Russell 2000® 1.5x Strategy | 13.00 | 0.00% | 0.00% | Mar 2022 |
| Rydex Var Russell 2000® 2x Strategy | 6.00 | 0.00% | +50.00% | Mar 2022 |
| BlackRock LifePath Idx Cons 2065 Fund F | 1.00 | 0.00% | 0.00% | Feb 2022 |
Top institutions holding KLDO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Artal Group S A | 501K | 1.17% | 0.00% | Jun 2022 |
| Close Asset Management Limited | 100.00 | 0.00% | -98.73% | Jun 2022 |
| CapTrust Financial Advisors | 0.00 | 0.00% | -100.00% | Jun 2022 |
| State Street Corporation | 0.00 | 0.00% | -100.00% | Jun 2022 |
| Palo Alto Investors, LLC | 0.00 | 0.00% | -100.00% | Jun 2022 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Jun 2022 |
| Northern Trust Corp | 0.00 | 0.00% | -100.00% | Jun 2022 |
| Federated Hermes Inc | 0.00 | 0.00% | -100.00% | Jun 2022 |
| State Of Wisconsin Investment Board | 0.00 | 0.00% | -100.00% | Jun 2022 |
| Barclays PLC | 0.00 | 0.00% | -100.00% | Jun 2022 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Jun 2022 |
| Millennium Management LLC | 0.00 | 0.00% | -100.00% | Jun 2022 |
| Harbourvest Partners, LLC | 0.00 | 0.00% | -100.00% | Jun 2022 |
| BNP Paribas Arbitrage, SA | 0.00 | 0.00% | -100.00% | Jun 2022 |
| U.S. Bancorp | 0.00 | 0.00% | -100.00% | Jun 2022 |
| Amalgamated Financial Corp | 0.00 | 0.00% | -100.00% | Jun 2022 |
| State Board Of Admin Of Florida Retir | 0.00 | 0.00% | -100.00% | Jun 2022 |
| Endurance Wealth Management, Inc. | 0.00 | 0.00% | -100.00% | Jun 2022 |
| American International Group Inc | 0.00 | 0.00% | -100.00% | Jun 2022 |
| New York State Common Retirement Fund | 0.00 | 0.00% | -100.00% | Jun 2022 |
Kaleido Biosciences Inc company profile
- Company name
- Kaleido Biosciences Inc
- Ticker
- KLDO.US
- Exchange
- USA Stocks
- Listed since
- Feb 28, 2019
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 76
- Fiscal year end
- December
- Address
- 65 Hayden Avenue, Lexington, MA, United States, 02421
- Phone
- 617 674 9000
- Website
- kaleido.com
About Kaleido Biosciences Inc
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Kaleido Biosciences Inc management
1- Dr. Mark A. Wingertzahn Ph.D.Senior VP of R&D and Head of Development · born 1972